Role of glycogen synthase kinase-3B on tau phosphorylation in alzheimer’s disease

Advances in Medicine and Biology

Volumn 2, Issue , 2010, Pages 197-210

  Resende, Rosa ^a   Oliveira, Catarina Resende ^a   Pereira, Cláudia M F ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Amyloid beta; Glycogen synthase kinase 3 ; Tau; Tauopathies

Indexed keywords

EID: 85017063867     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (96)

1. Alonso, A. C., Zaidi, T., Grundke-Iqbal, I. & Iqbal, K. (1994). Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer’s disease. Proc. Natl. Acad. Sci., U S A., 91, 5562-5566.
2. Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T. & Hyman, B. T. (1992). Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology, 42, 631-639.
3. Avila, J. (2006). Tau protein, the main component of paired helical filaments. J. Alzheimers Dis, 9, 171-175.
4. Baki, L., Neve, R. L., Shao, Z., Shioi, J., Georgakopoulos, A. & Robakis, N. K. (2008). Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling. J. Neurosci, 28, 483-490.
5. Balaraman, Y., Limaye, A. R., Levey, A. I. & Srinivasan, S. (2006). Glycogen synthase kinase 3beta and Alzheimer’s disease: pathophysiological and therapeutic significance. Cell. Mol. Life Sci., 63, 1226-1235.
6. Barten, D. M. & Albright, C. F. (2008). Therapeutic strategies for Alzheimer’s disease. Mol. Neurobiol, 37, 171-186.
7. Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A. C., Jerning, E., Markgren, P. O., Borgegård, T., Nylöf, M., Giménez-Cassina, A., Hernández, F., Lucas, J. J., Díaz-Nido, J. & Avila, J. (2003). Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem., 278, 45937-45945.
8. Blalock, E. M., Geddes, J. W., Chen, K. C., Porter, N. M., Markesbery, W. R. & Landfield, P. W. (2004). Incipient Alzheimer’s disease: microarray correlation analyses reveal major Rosa Resende, Catarina Resende Oliveira and Cláudia MF Pereira 204 transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. U S A, 10, 2173-2178.
9. Blennow, K., de Leon, M. J. & Zetterberg, H. (2006). Alzheimer’s disease. Lancet, 368, 387-403.
10. Bloom, G. S., Ren, K. & Glabe, C. G. (2005). Cultured cell and transgenic mouse models for tau pathology linked to beta-amyloid. Biochim. Biophys. Acta, 1739, 116-124.
11. Blurton-Jones, M. & Laferla, F. M. (2006). Pathways by which Abeta facilitates tau pathology. Curr. Alzheimer. Res., 3, 437-448.
12. Brewster, J. L., Linseman, D. A., Bouchard, R. J., Loucks, F. A., Precht, T. A., Esch, E. A. & Heidenreich, K. A. (2006). Endoplasmic reticulum stress and trophic factor withdrawal activate distinct signaling cascades that induce glycogen synthase kinase-3 beta and a caspase-9-dependent apoptosis in cerebellar granule neurons. Mol. Cell Neurosci, 32, 242-253.
13. Brion, J. P., Anderton, B. H., Authelet, M., Dayanandan, R., Leroy, K., Lovestone, S., Octave, J. N., Pradier, L., Touchet, N. & Tremp, G. (2001). Neurofibrillary tangles and tau phosphorylation. Biochem. Soc. Symp., 67, 81-88.
14. Busciglio, J. & Yankner, B. A. (1995). Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro. Nature, 378, 776-779.
15. Caccamo, A., Oddo, S., Tran, L. X. & LaFerla, F. M. (2007). Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol, 170, 1669-1675.
16. Cohen, P. & Frame, S. (2001). The renaissance of GSK3. Nat. Rev. Mol. Cell Biol., 2, 769-776.
17. Cross, D. A., Culbert, A. A., Chalmers, K. A., Facci, L., Skaper, S. D. & Reith, A. D. (2001). Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem, 77, 94-102.
18. Crouch, P. J., Hung, L. W., Adlard, P. A., Cortes, M., Lal, V., Filiz, G., Perez, K. A., Nurjono, M., Caragounis, A., Du, T., Laughton, K., Volitakis, I., Bush, A. I., Li, Q. X., Masters, C. L., Cappai, R., Cherny, R. A., Donnelly, P. S., White, A. R. & Barnham, K. J. (2009). Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc. Natl. Acad. Sci., U S A., 106, 381-386.
19. De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., Chen-Dodson, E., Kinney, G. G. & Klein, W. L. (2008). Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers. Neurobiol Aging, 29, 1334-1347.
20. Doble, B. W. & Woodgett, J. R. (2003). GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci., 116, 1175-1186.
21. Dunn, N., Holmes, C. & Mullee, M. (2005). Does lithium therapy protect against the onset of dementia? Alzheimer Dis. Assoc. Disord, 19, 20-22.
22. Ebneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B. & Mandelkow, E. (1998). Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer’s disease. J. Cell Biol., 143, 777-794.
23. Engel, T., Goñi-Oliver, P., Lucas, J. J., Avila, J. & Hernández, F. (2006). Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem, 99, 1445-1455.
24. Fernández-Vizarra, P., Fernández, A. P., Castro-Blanco, S., Serrano, J., Bentura, M. L., Martínez-Murillo, R., Martínez, A. & Rodrigo, J. (2004). Intra-and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer’s disease. Histol. Histopathol, 19, 823-844.
25. Ferreiro, E., Oliveira, C. R. & Pereira, C. (2004). Involvement of endoplasmic reticulum Ca2+ release through ryanodine and inositol 1,4,5-triphosphate receptors in the neurotoxic effects induced by the amyloid-β peptide. J. Neurosci. Res., 76, 872-880.
26. Ferreiro, E., Oliveira, C. R. & Pereira C. (2008). The release of calcium from the Endoplasmic reticulum induced by amyloid-beta and prion peptides activates the mitochondrial apoptotic pathway. Neurobiol. Dis., 30, 331-342.
27. Ferreiro, E., Resende, R., Costa, R., Oliveira, C. R. & Pereira, C. (2006). An endoplasmicreticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity. Neurobiol. Dis., 23, 669-678.
28. Gong, C. X. & Iqbal, K. (2008). Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem., 15, 2321-2328.
29. Grimes, C. A. & Jope, R. S. (2001). The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol, 65, 391-426.
30. Grundke-Iqbal, I., Iqbal, K., George, L., Tung, Y. C., Kim, K. S. & Wisniewski, H. M. (1989). Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A, 86, 2853-2857.
31. Guo, J. P., Arai, T., Miklossy, J. & McGeer, P. L. (2006). Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A, 103, 1953-1958.
32. Haass, C. & Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol., 8, 101-112.
33. Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M. S., Jin, O. & Woodgett, J. R. (2000). Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature, 406, 86-90.
34. Hooper, C., Killick, R. & Lovestone, S. (2008). The GSK3 hypothesis of Alzheimer’s disease. J. Neurochem, 104, 1433-1439.
35. Hoozemans, J. J., Veerhuis, R., Van Haastert, E. S., Rozemuller, J. M., Baas, F., Eikelenboom, P. & Scheper, W. (2005). The unfolded protein response is activated in Alzheimer’s disease. Acta Neuropathol, 110, 165-172.
36. Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F. & Woodgett, J. R. (1993). Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J, 12, 803-808.
37. Ishiguro, K., Omori, A., Takamatsu, M., Sato, K., Arioka, M., Uchida, T. & Imahori, K. (1992). Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci. Lett, 148, 202-206.
38. Ishiguro, K., Shiratsuchi, A., Sato, S., Omori, A., Arioka, M., Kobayashi, S., Uchida, T. & Imahori, K. (1993). Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett, 325, 167-172.
39. Ishizawa, T., Sahara, N., Ishiguro, K., Kersh, J., McGowan, E., Lewis, J., Hutton, M., Dickson, D. W. & Yen, S. H. (2003). Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am. J. Pathol, 163, 1057-1067.
40. Jope, R. S., Yuskaitis, C. J. & Beurel, E. (2007). Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res., 32, 577-595.
41. Kaidanovich-Beilin, O. & Eldar-Finkelman, H. (2006). Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J. Pharmacol. Exp. Ther., 316, 17-24.
42. Kang, D. E., Soriano, S., Frosch, M. P., Collins, T., Naruse, S., Sisodia, S. S., Leibowitz, G., Levine, F. & Koo, E. H. (1999). Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer’s disease-linked PS1 mutants in the beta-catenin-signaling pathway. J. Neurosci, 19, 4229-4237.
43. Koh, S. H., Noh, M. Y. & Kim, S. H. (2008). Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res., 1188, 254-262.
44. Le Corre, S., Klafki, H. W., Plesnila, N., Hübinger, G., Obermeier, A., Sahagún, H., Monse, B., Seneci, P., Lewis, J., Eriksen, J., Zehr, C., Yue, M., McGowan, E., Dickson, D. W., Hutton, M. & Roder, H. M. (2006). An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl. Acad. Sci. U S A, 103, 9673-9678.
45. Lee, K. Y., Koh, S. H., Noh, M. Y., Kim, S. H. & Lee, Y. J. (2008). Phosphatidylinositol-3-kinase activation blocks amyloid beta-induced neurotoxicity. Toxicology, 243, 43-50.
46. Leroy, K., Yilmaz, Z. & Brion, J. P. (2007). Increased level of active GSK-3beta in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol. Appl. Neurobiol, 33, 43-55.
47. Liu, S. J., Zhang, A. H., Li, H. L., Wang, Q., Deng, H. M., Netzer, W. J., Xu, H. & Wang, J. Z. (2003). Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J. Neurochem, 87, 1333-1344.
48. Lopes, J. P., Oliveira, C. R. & Agostinho, P. (2007). Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer’s disease and prion-related encephalopathies. Cell Mol. Neurobiol, 27, 943-957.
49. Lovestone, S., Reynolds, C. H., Latimer, D., Davis, D. R., Anderton, B. H., Gallo, J. M., Hanger, D., Mulot, S., Marquardt, B. & Stabel, S., et al. (1994). Alzheimer’s disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol., 4, 1077-1086.
50. Ma, Q. L., Lim, G. P., Harris-White, M. E., Yang, F., Ambegaokar, S. S., Ubeda, O. J., Glabe, C. G., Teter, B., Frautschy, S. A. & Cole, G. M. (2006). Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J. Neurosci. Res., 83, 374-384.
51. MacAulay, K. Doble, B. W., Patel, S., Hansotia, T., Sinclair, E. M., Drucker, D. J., Nagy, A. & Woodgett, J. R. (2007). Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab, 6, 329-337.
52. Magrané, J., Rosen, K. M., Smith, R. C., Walsh, K., Gouras, G. K. & Querfurth, H. W. (2005). Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response. J. Neurosci, 25, 10960-10969.
53. Mandelkow, E. M., Thies, E., Trinczek, B., Biernat, J. & Mandelkow, E. (2004). MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J. Cell Biol., 167, 99-110.
54. Mercado-Gómez, O., Hernández-Fonseca, K., Villavicencio-Queijeiro, A., Massieu, L., Chimal-Monroy, J. & Arias, C. (2008). Inhibition of Wnt and P13K signaling modulates GSK-3beta activity and induces morphological changes in cortical neurons: role of tau phosphorylation. Neurochem. Res., 33, 1599-1609.
55. Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., Burns, M., Krishnamurthy, P., Wen, Y., Bhat, R., Lewis, J., Dickson, D. & Duff, K. (2005). Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci., USA, 102, 6990-7095.
56. Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H. & LaFerla, F. M. (2004). Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 43, 321-332.
57. Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B. P. & LaFerla, F. M. (2003). Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol. Aging, 24, 1063-1070.
58. Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y. & LaFerla, F. M. (2003). Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular A and synaptic dysfunction. Neuron, 39, 409-421.
59. Oddo, S., Caccamo, A., Tseng, B., Cheng, D., Vasilevko, V., Cribbs, D. H. & LaFerla, F. M. (2008). Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J. Neurosci, 28, 12163-12175.
60. Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L. & LaFerla, F. M. (2006a). Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer’s disease. A link between Abeta and tau pathology. J Biol Chem., 281, 1599-1604.
61. Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D. H. & LaFerla, F. M. (2006b). Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem., 281, 39413-39423.
62. Pei, J. J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B. & Cowburn, R. F. (1997). Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer’s disease neurofibrillary changes. J. Neuropathol. Exp. Neurol, 58, 1010-1019.
63. Phiel, C. J., Wilson, C. A., Lee, V. M. & Klein, P. S. (2003). GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature, 423, 435-439.
64. Plattner, F., Angelo, M. & Giese, K. P. (2006). The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem., 281, 25457-25465.
65. Qing, H., He, G., Ly, P. T., Fox, C. J., Staufenbiel, M., Cai, F., Zhang, Z., Wei, S., Sun, X., Chen, C. H., Zhou, W., Wang, K. & Song, W. (2008). Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer’s disease mouse models. J. Exp. Med, 205, 2781-2789.
66. Rametti, A., Esclaire, F., Yardin, C., Cogné, N. & Terro, F. (2008). Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection. Neurosci. Lett, 434, 93-98.
67. Rankin, C. A., Sun, Q. & Gamblin, T. C. (2008). Pre-assembled tau filaments phosphorylated by GSK-3b form large tangle-like structures. Neurobiol. Dis., 31, 368-377.
68. Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P. & Ferreira, A. (2002). Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci., U S A, 99, 6364-6369.
69. Resende, R., Ferreiro, E., Pereira, C. & Oliveira, C. R. (2008a). ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation. J. Neurosci. Res., 86, 2091-2099.
70. Resende, R., Ferreiro, E., Pereira, C. & Oliveira, C. R. (2008b). Neurotoxic effect of oligomeric and fibrillar species of Aβ1-42 peptide. Involvement of ER calcium release in oligomers-induced cell death. Neuroscience, 155, 725-737.
71. Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G. Q. & Mucke, L. (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science, 316, 750-754.
72. Rockenstein, E., Torrance, M., Adame, A., Mante, M., Baron, P., Rose, J. B., Crews, L. & Masliah, E. (2007). Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer’s disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci, 27, 1981-1991.
73. Rui, Y., Tiwari, P., Xie, Z. & Zheng, J. Q. (2006). Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons. J. Neurosci, 26, 10480-10487.
74. Shelton, S. B. & Johnson, G. V. (2004). Cyclin-dependent kinase-5 in neurodegeneration. J. Neurochem, 88, 1313-1326.
75. Song, L., De Sarno, P. & Jope, R. S. (2002). Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J. Biol. Chem., 277, 44701-44708.
76. Sontag, E., Luangpirom, A., Hladik, C., Mudrak, I., Ogris, E., Speciale, S. & White, CL 3rd. (2004). Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer’s disease pathology. J. Neuropathol. Exp. Neurol, 63, 287-301.
77. Srinivasan, S., Ohsugi, M., Liu, Z., Fatrai, S., Bernal-Mizrachi, E. & Permutt, M. A. (2005). Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3beta in mouse insulinoma cells. Diabetes, 54, 968-975.
78. Stamer, K., Vogel, R., Thies, E., Mandelkow, E. & Mandelkow, E. M. (2002). Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol., 156, 1051-1063.
79. Sun, X., Sato, S., Murayama, O., Murayama, M., Park, J. M., Yamaguchi, H. & Takashima, A. (2002). Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neuroscience Lett, 321, 61-64.
80. Takadera, T., Fujibayashi, M., Kaniyu, H., Sakota, N. & Ohyashiki, T. (2007). Caspase-dependent apoptosis induced by thapsigargin was prevented by glycogen synthase kinase-3 inhibitors in cultured rat cortical neurons. Neurochem. Res., 32, 1336-1342.
81. Takadera, T., Yoshikawa, R. & Ohyashiki, T. (2006). Thapsigargin-induced apoptosis was prevented by glycogen synthase kinase-3 inhibitors in PC12 cells. Neurosci. Lett, 408, 124-128.
82. Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Yamaguchi, H., Sugihara, S. & Wolozin, B. (1998). Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc. Natl. Acad. Sci. U S A, 95, 9637-9641.
83. Takashima, A., Noguchi, K., Michel, G., Mercken, M., Hoshi, M., Ishiguro, K. & Imahori, K. (1996). Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci. Lett, 203, 33-36.
84. Tanabe, K., Liu, Z., Patel, S., Doble, B. W., Li, L., Cras-Méneur, C., Martinez, S. C., Welling, C. M., White, M. F., Bernal-Mizrachi, E., Woodgett, J. R. & Permutt, M. A. (2008). Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol., 6, 307-318.
85. Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H. & Van Leuven, F. (2008). Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am. J. Pathol, 172, 786-798., 2008.
86. Tomidokoro, Y., Ishiguro, K., Harigaya, Y., Matsubara, E., Ikeda, M., Park, JM., Yasutake, K., Kawarabayashi, T., Okamoto, K. & Shoji, M. (2001). Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice. Neurosci. Lett, 299, 169-172.
87. Turenne, G. A. & Price, B. D. (2001). Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53‘s transcriptional activity. BMC Cell Biol, 2, 12-20.
88. Troussard, A. A., Tan, C., Yoganathan, T. N. & Dedhar, S. (1999). Cell-extracellular matrix interactions stimulate the AP-1 transcription factor in an integrin-linked kinase- and glycogen synthase kinase 3-dependent manner. Mol. Cell Biol., 19, 7420-7427.
89. Tseng, B. P., Green, K. N., Chan, J. L., Blurton-Jones, M. & Laferla, F. M. (2008). Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging, 29, 1607-1618.
90. Uemura, K., Kuzuya, A., Shimozono, Y., Aoyagi, N., Ando, K., Shimohama, S. & Kinoshita, A. (2007). GSK3beta activity modifies the localization and function of presenilin 1. J. Biol. Chem., 282, 15823-15832.
91. Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J. Q. & Lee, V. M. (2001). PP2A mRNA expression is quantitatively decreased in Alzheimer’s disease hippocampus. Exp. Neurol, 168, 402-412.
92. Wang, J. Z., Grundke-Iqbal, I. & Iqbal, K. (2007). Kinases and phosphatases and tau sites involved in Alzheimer’s neurofibrillary degeneration. Eur. J. Neurosci, 25, 59-68.
93. Welsh, G. I. & Proud, C. G. (1993). Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem. J, 294, 625-629.
94. Wen, Y., Planel, E., Herman, M., Figueroa, H. Y., Wang, L., Liu, L., Lau, L. F., Yu, W. H. & Duff, K. E. (2008). Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci, 28, 2624-2632.
95. Yamaguchi, H., Ishiguro, K., Uchida, T., Takashima, A., Lemere, C. A. & Imahori, K. (1996). Preferential labeling of Alzheimer’s neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol, 92, 232-241.
96. Yoshida, I., Monji, A., Tashiro, K., Nakamura, K., Inoue, R. & Kanba, S. (2006). Depletion of intracellular Ca2+ store itself may be a major factor in thapsigargin-induced ER stress and apoptosis in PC12 cells. Neurochem. Int., 48, 696-702.